Bionano Genomics

Summary

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

History

Bionano Genomics was founded in 2006 by biologists, computer scientists and engineers to develop life science tools based on new nanoscale detection technologies. In 2011, Bionano established a new headquarters and opened its own lab in La Jolla, California. In 2017, Bionano released its first commercial instrument, the Saphyr, and established a fully automated production and quality control system at its La Jolla facility

Mission

Bionano's mission is to improve genetically based treatments and diagnoses of diseases through ultra-sensitive and ultra-specific structural variation detection.

Vision

Bionano's vision is to be the leading provider of high-sensitivity and high-specificity structural variation detection for research and clinical applications

References

https://in.investing.com/equities/bionano-genomics

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/bionanomatrix

https://finance.yahoo.com/quote/BNGO/

https://www.bionanogenomics.com

https://sec.report/CIK/0001411690

Contacts

Follow Us

Bionano Genomics

Share

Contacts

Follow Us